Teva (TEVA) CEO sells 6,153 shares to cover RSU tax

Rhea-AI Filing Summary

Teva Pharmaceutical Industries President and CEO Richard D. Francis reported routine equity compensation activity involving restricted share units and related share sales. He exercised 13,043 restricted share units into ordinary shares and sold 6,153 ordinary shares at $34.35 per share to cover tax withholding obligations tied to the vesting. Following these transactions, he directly holds 1,183,682 ordinary shares and 39,130 restricted share units, with the sale executed under a pre-arranged Rule 10b5-1 trading plan.

Insights

Equity compensation and insider trading analyst

Routine RSU vesting with tax-related sale under a 10b5-1 plan.

The CEO of Teva Pharmaceutical Industries, Richard D. Francis, converted 13,043 restricted share units into ordinary shares and sold 6,153 shares at $34.35 per share. Footnotes explain the sale was required to cover tax withholding from the RSU vesting.

The filing notes the transaction occurred under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than opportunistic market timing. After these moves, he holds 1,183,682 ordinary shares and 39,130 restricted share units, suggesting a substantial continuing equity stake.

Insider Trade Summary 10b5-1

Net Seller: 6,153 shares ($211,356)

Net Sell 3 txns

Insider Francis Richard D

Role President and CEO

Sold 6,153 shs ($211K)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	13,043	$0.00	--
Exercise	Ordinary Shares	13,043	$0.00	--
Sale	Ordinary Shares	6,153	$34.35	$211K

Holdings After Transaction: Restricted Share Units — 39,130 shares (Direct, null); Ordinary Shares — 1,183,682 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.

Key Figures

Shares sold: 6,153 shares Sale price: $34.35 per share RSUs exercised: 13,043 units +3 more

6 metrics

Shares sold 6,153 shares Ordinary shares sold at $34.35 on June 5, 2026

Sale price $34.35 per share Price for 6,153 ordinary shares sold

RSUs exercised 13,043 units Restricted share units converted into ordinary shares

Shares held after transactions 1,183,682 shares Ordinary shares directly owned post-transaction

RSUs remaining 39,130 units Restricted share units outstanding after the reported vesting

Future RSU vesting dates 2027, 2028, 2029 tranches Portions vest on June 5 of each year

Key Terms

Rule 10b5-1 trading plan, Restricted share units, American Depositary Shares, tax withholding obligations

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Restricted share units financial

"Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026..."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

tax withholding obligations financial

"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francis Richard D

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/05/2026		M		13,043	A	(2)	1,183,682	D
Ordinary Shares(1)	06/05/2026		S(3)		6,153(4)	D	$34.35	1,177,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	06/05/2026		M			13,043	(5)	(5)	Ordinary Shares(1)	13,043	$0	39,130	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Teva (TEVA) CEO Richard D. Francis report?

Richard D. Francis reported exercising 13,043 restricted share units into ordinary shares and selling 6,153 ordinary shares at $34.35 per share. These actions reflect routine equity compensation activity tied to a vesting event rather than a discretionary open-market purchase.

Why did the Teva (TEVA) CEO sell 6,153 ordinary shares?

The 6,153 ordinary shares were sold to cover tax withholding obligations arising from the vesting of restricted share units. A footnote specifies this requirement, indicating the sale was primarily for tax payment rather than a shift in his economic exposure to Teva stock.

Was the Teva (TEVA) CEO’s share sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan adopted on November 14, 2025. Such plans pre-schedule trades, reducing the significance of short-term market conditions for interpreting the timing of this sale.

How many Teva (TEVA) shares does the CEO hold after these transactions?

After these transactions, Richard D. Francis directly holds 1,183,682 ordinary shares. He also has 39,130 restricted share units outstanding, which represent additional contingent rights to receive ordinary shares or their cash value at future vesting dates.

What restricted share unit activity did Teva (TEVA) disclose for its CEO?

The filing shows 13,043 restricted share units were exercised into ordinary shares on June 5, 2026. A footnote explains these units were part of a June 5, 2025 grant that vests annually through June 5, 2029, with remaining tranches scheduled to vest in later years.

How many restricted share units remain outstanding for the Teva (TEVA) CEO?

Following the reported vesting and conversion, 39,130 restricted share units remain outstanding for Richard D. Francis. These units relate to a grant with portions vesting on June 5, 2027, June 5, 2028, and June 5, 2029, subject to the plan’s terms.